These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 20049837)

  • 1. Additional value of EGFR downstream signaling phosphoprotein expression to KRAS status for response to anti-EGFR antibodies in colorectal cancer.
    Perkins G; Lièvre A; Ramacci C; Méatchi T; de Reynies A; Emile JF; Boige V; Tomasic G; Bachet JB; Bibeau F; Bouché O; Penault-Llorca F; Merlin JL; Laurent-Puig P
    Int J Cancer; 2010 Sep; 127(6):1321-31. PubMed ID: 20049837
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of MicroRNA-31-5p with Clinical Efficacy of Anti-EGFR Therapy in Patients with Metastatic Colorectal Cancer.
    Igarashi H; Kurihara H; Mitsuhashi K; Ito M; Okuda H; Kanno S; Naito T; Yoshii S; Takahashi H; Kusumi T; Hasegawa T; Sukawa Y; Adachi Y; Okita K; Hirata K; Imamura Y; Baba Y; Imai K; Suzuki H; Yamamoto H; Nosho K; Shinomura Y
    Ann Surg Oncol; 2015 Aug; 22(8):2640-8. PubMed ID: 25472647
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of pEGFR and pAKT as response-predictive biomarkers for RAS wild-type patients to anti-EGFR monoclonal antibodies in metastatic colorectal cancers.
    Harlé A; Salleron J; Perkins G; Pilati C; Blons H; Laurent-Puig P; Merlin JL
    Br J Cancer; 2015 Aug; 113(4):680-5. PubMed ID: 26171935
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical relevance of KRAS-mutated subclones detected with picodroplet digital PCR in advanced colorectal cancer treated with anti-EGFR therapy.
    Laurent-Puig P; Pekin D; Normand C; Kotsopoulos SK; Nizard P; Perez-Toralla K; Rowell R; Olson J; Srinivasan P; Le Corre D; Hor T; El Harrak Z; Li X; Link DR; Bouché O; Emile JF; Landi B; Boige V; Hutchison JB; Taly V
    Clin Cancer Res; 2015 Mar; 21(5):1087-97. PubMed ID: 25248381
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EGFR and downstream genetic alterations in KRAS/BRAF and PI3K/AKT pathways in colorectal cancer: implications for targeted therapy.
    Berg M; Soreide K
    Discov Med; 2012 Sep; 14(76):207-14. PubMed ID: 23021375
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The influence of KRAS and BRAF mutations on the efficacy of cetuximab-based first-line therapy of metastatic colorectal cancer: an analysis of the AIO KRK-0104-trial.
    Modest DP; Jung A; Moosmann N; Laubender RP; Giessen C; Schulz C; Haas M; Neumann J; Boeck S; Kirchner T; Heinemann V; Stintzing S
    Int J Cancer; 2012 Aug; 131(4):980-6. PubMed ID: 21960311
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EGFR fluorescence in situ hybridization pattern of chromosome 7 disomy predicts resistance to cetuximab in KRAS wild-type metastatic colorectal cancer patients.
    Li YH; Wang F; Shen L; Deng YM; Shao Q; Feng F; An X; Wang FH; Wang ZQ; Xu RH; Shao JY
    Clin Cancer Res; 2011 Jan; 17(2):382-90. PubMed ID: 20884623
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The RAS paradox of the EGFR-targeted therapy in colorectal cancer].
    Tímár J; Láng I
    Magy Onkol; 2008 Jun; 52(2):185-91. PubMed ID: 18640895
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A systematic review and meta-analysis of KRAS status as the determinant of response to anti-EGFR antibodies and the impact of partner chemotherapy in metastatic colorectal cancer.
    Adelstein BA; Dobbins TA; Harris CA; Marschner IC; Ward RL
    Eur J Cancer; 2011 Jun; 47(9):1343-54. PubMed ID: 21550229
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of progression-free survival, overall survival, and patient-reported outcomes by skin toxicity and KRAS status in patients receiving panitumumab monotherapy.
    Peeters M; Siena S; Van Cutsem E; Sobrero A; Hendlisz A; Cascinu S; Kalofonos H; Devercelli G; Wolf M; Amado RG
    Cancer; 2009 Apr; 115(7):1544-54. PubMed ID: 19189371
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular dissection of effector mechanisms of RAS-mediated resistance to anti-EGFR antibody therapy.
    Kasper S; Reis H; Ziegler S; Nothdurft S; Mueller A; Goetz M; Wiesweg M; Phasue J; Ting S; Wieczorek S; Even A; Worm K; Pogorzelski M; Breitenbuecher S; Meiler J; Paul A; Trarbach T; Schmid KW; Breitenbuecher F; Schuler M
    Oncotarget; 2017 Jul; 8(28):45898-45917. PubMed ID: 28507280
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heterogeneity of epidermal growth factor receptor status and mutations of KRAS/PIK3CA in circulating tumor cells of patients with colorectal cancer.
    Gasch C; Bauernhofer T; Pichler M; Langer-Freitag S; Reeh M; Seifert AM; Mauermann O; Izbicki JR; Pantel K; Riethdorf S
    Clin Chem; 2013 Jan; 59(1):252-60. PubMed ID: 23136247
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of the concordance in the EGFR pathway status between primary tumors and related metastases of colorectal cancer patients:implications for cancer therapy.
    Cejas P; López-Gómez M; Aguayo C; Madero R; Moreno-Rubio J; de Castro Carpeño J; Belda-Iniesta C; Barriuso J; Moreno García V; Díaz E; Burgos E; Gonzalez-Barón M; Feliu J
    Curr Cancer Drug Targets; 2012 Feb; 12(2):124-31. PubMed ID: 22229245
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Association of epithermal growth factor receptor expression and its downstream gene mutation status with radiosensitivity of colorectal carcinoma cell lines in vitro].
    Zuo ZG; Yu ZQ; Gao XH; Wang H; Zhang C; Liu QZ; Han YF; Chen LP; Zhang XQ; Fu CG
    Zhonghua Wei Chang Wai Ke Za Zhi; 2013 Aug; 16(8):753-8. PubMed ID: 23980047
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Roles of EGFR and KRAS and their downstream signaling pathways in pancreatic cancer and pancreatic cancer stem cells.
    Fitzgerald TL; Lertpiriyapong K; Cocco L; Martelli AM; Libra M; Candido S; Montalto G; Cervello M; Steelman L; Abrams SL; McCubrey JA
    Adv Biol Regul; 2015 Sep; 59():65-81. PubMed ID: 26257206
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of KRAS Mutation Status on Outcomes in Metastatic Colon Cancer Patients without Anti-Epidermal Growth Factor Receptor Therapy.
    Kim ST; Park KH; Kim JS; Shin SW; Kim YH
    Cancer Res Treat; 2013 Mar; 45(1):55-62. PubMed ID: 23613671
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Status of components in EGFR-related signal transduction as predictive markers for anti-EGFR antibody therapy in colorectal cancer treatment].
    Shimodaira H; Soeda H; Komine K; Ishioka C
    Gan To Kagaku Ryoho; 2009 Jul; 36(7):1063-6. PubMed ID: 19620792
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Personalized cancer treatment and the myth of KRAS wild-type colon tumors.
    Parsons BL; Myers MB
    Discov Med; 2013 Apr; 15(83):259-67. PubMed ID: 23636143
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EGF-Induced Acetylation of Heterogeneous Nuclear Ribonucleoproteins Is Dependent on KRAS Mutational Status in Colorectal Cancer Cells.
    Roda D; Castillo J; Telechea-Fernández M; Gil A; López-Rodas G; Franco L; González-Rodríguez P; Roselló S; Pérez-Fidalgo JA; García-Trevijano ER; Cervantes A; Zaragozá R
    PLoS One; 2015; 10(6):e0130543. PubMed ID: 26110767
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heteronemin and Tetrac Induce Anti-Proliferation by Blocking EGFR-Mediated Signaling in Colorectal Cancer Cells.
    Unson S; Chang TC; Yang YN; Wang SH; Huang CH; Crawford DR; Huang HM; Li ZL; Lin HY; Whang-Peng J; Wang K; Davis PJ; Li WS
    Mar Drugs; 2022 Jul; 20(8):. PubMed ID: 36005485
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.